Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Takamitsu Hattori"'
Autor:
Niklas Ravn-Boess, Nainita Roy, Takamitsu Hattori, Devin Bready, Hayley Donaldson, Christopher Lawson, Cathryn Lapierre, Aryeh Korman, Tori Rodrick, Enze Liu, Joshua D. Frenster, Gabriele Stephan, Jordan Wilcox, Alexis D. Corrado, Julia Cai, Rebecca Ronnen, Shuai Wang, Sara Haddock, Jonathan Sabio Ortiz, Orin Mishkit, Alireza Khodadadi-Jamayran, Aris Tsirigos, David Fenyö, David Zagzag, Julia Drube, Carsten Hoffmann, Fabiana Perna, Drew R. Jones, Richard Possemato, Akiko Koide, Shohei Koide, Christopher Y. Park, Dimitris G. Placantonakis
Publikováno v:
Cell Reports, Vol 42, Iss 11, Pp 113374- (2023)
Summary: Glioblastoma (GBM) is the most common and aggressive primary brain malignancy. Adhesion G protein-coupled receptors (aGPCRs) have attracted interest for their potential as treatment targets. Here, we show that CD97 (ADGRE5) is the most promi
Externí odkaz:
https://doaj.org/article/e954f101e34e4454841a124bf6a6e405
Autor:
Kai Wen Teng, Steven T. Tsai, Takamitsu Hattori, Carmine Fedele, Akiko Koide, Chao Yang, Xuben Hou, Yingkai Zhang, Benjamin G. Neel, John P. O’Bryan, Shohei Koide
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Most oncogenic RAS mutants remain undruggable. Here, the authors developed monobodies that selectively recognize the active state of KRAS(G12V) and KRAS(G12C) and demonstrated their utility in inhibiting RAS functions through inhibition and degradati
Externí odkaz:
https://doaj.org/article/1c4337f6a3694e9b96918c1bb0fcb1f7
Autor:
Maria G. Noval, Maria E. Kaczmarek, Akiko Koide, Bruno A. Rodriguez-Rodriguez, Ping Louie, Takuya Tada, Takamitsu Hattori, Tatyana Panchenko, Larizbeth A. Romero, Kai Wen Teng, Andrew Bazley, Maren de Vries, Marie I. Samanovic, Jeffrey N. Weiser, Ioannis Aifantis, Joan Cangiarella, Mark J. Mulligan, Ludovic Desvignes, Meike Dittmann, Nathaniel R. Landau, Maria Aguero-Rosenfeld, Shohei Koide, Kenneth A. Stapleford
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Understanding antibody responses to SARS-CoV-2 is indispensable for the development of containment measures to overcome the current COVID-19 pandemic. Recent studies showed that serum from convalescent patients can display variable neutraliz
Externí odkaz:
https://doaj.org/article/431b486be8244906b88b8f8c1a505e1f
Autor:
Maso, Lorenzo, Rajak, Epsa, Injin Bang, Akiko Koide, Takamitsu Hattori, Neel, Benjamin G., Shohei Koide
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America; 5/28/2024, Vol. 121 Issue 22, p1-10, 31p
Autor:
Jiehui Deng, David H. Peng, David Fenyo, Hao Yuan, Alfonso Lopez, Daniel S. Levin, Mary Meynardie, Mari Quinteros, Michela Ranieri, Soumyadip Sahu, Sally C. M. Lau, Elaine Shum, Vamsidhar Velcheti, Salman R. Punekar, Natasha Rekhtman, Catríona M. Dowling, Vajira Weerasekara, Yun Xue, Hongbin Ji, Yik Siu, Drew Jones, Aaron N. Hata, Takeshi Shimamura, John T. Poirier, Charles M Rudin, Takamitsu Hattori, Shohei Koide, Thales Papagiannakopoulos, Benjamin G. Neel, Nabeel Bardeesy, Kwok-kin Wong
Publikováno v:
bioRxiv
LKB1/STK11 is a serine/threonine kinase that plays a major role in controlling cell metabolism, resulting in potential therapeutic vulnerabilities in LKB1-mutant cancers. Here, we identify the NAD+degrading ectoenzyme, CD38, as a new target in LKB1-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::664879e61c343e2d903f560a28e6eb38
https://europepmc.org/articles/PMC10153147/
https://europepmc.org/articles/PMC10153147/
Autor:
Shohei Koide, Benjamin G. Neel, Injin Bang, Padma Akkapeddi, James Hayman, Akiko Koide, Kiyomi Y. Araki, Lorenzo Maso, Takamitsu Hattori
Intracellular oncoproteins can be inhibited with targeted therapy, but responses are not durable. Immune therapies can be curative, but most oncogene-driven tumors are unresponsive to these agents. Fragments of intracellular oncoproteins can act as n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54e832e5573620213e2f0cc7d655291b
https://doi.org/10.1158/2159-8290.c.6549729.v1
https://doi.org/10.1158/2159-8290.c.6549729.v1
Autor:
Shohei Koide, Benjamin G. Neel, Injin Bang, Padma Akkapeddi, James Hayman, Akiko Koide, Kiyomi Y. Araki, Lorenzo Maso, Takamitsu Hattori
Supplementary Figure S1 shows size exclusion chromatography profiles of products of the refolding reactions for p/MHCs utilized in this study. Supplementary Figure S2 shows binding properties of antibodies to sotorasib-KRAS(G12C) peptide conjugates i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9dd38cd406cacd8bb0922190f85887e
https://doi.org/10.1158/2159-8290.22541703.v1
https://doi.org/10.1158/2159-8290.22541703.v1
Autor:
Takamitsu Hattori, Lorenzo Maso, Kiyomi Y. Araki, Akiko Koide, James Hayman, Padma Akkapeddi, Injin Bang, Benjamin G. Neel, Shohei Koide
Publikováno v:
Cancer discovery.
Intracellular oncoproteins can be inhibited with targeted therapy, but responses are not durable. Immune therapies can be curative, but most oncogene-driven tumors are unresponsive to these agents. Fragments of intracellular oncoproteins can act as n
Autor:
Takamitsu Hattori, Padma Akkapeddi, Imran Khan, Akiko Koide, Eliezra Glasser, Gayatri Ketavarapu, Michael Whaby, Mariyam Zuberi, Kai Wen Teng, Julia Lefler, Lorenzo Maso, Injin Bang, Michael C. Ostrowski, John P. O’Bryan, Shohei Koide
Publikováno v:
Molecular Cancer Research. 21:B013-B013
The G12D mutation is among the most common KRAS mutations associated with cancer, in particular pancreatic cancer. Here, we have developed monobodies, small synthetic binding proteins, that are highly selective to KRAS(G12D) over KRAS(wild type) and
Autor:
Lorenzo Maso, Takamitsu Hattori, Kiyomi Araki, Akiko Koide, Epsa Rajak, James Hayman, Padma Akkapeddi, Injin Bang, Benjamin G. Neel, Shohei Koide
Publikováno v:
Molecular Cancer Research. 21:B020-B020
Covalent inhibitors against KRAS(G12C) represent major breakthroughs in the effort to directly and selectively target oncogenic RAS mutants. However, similar to other targeted therapies, they lack durability. Immune therapy can be curative, and fragm